The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mezigdomide Combinations Show Promise in Multiple Myeloma

2.

Patient Endured 9 Years of Chemotherapy for Cancer He Never Had

3.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

4.

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC

5.

Glioblastoma treatment breakthrough shows promise


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot